Alembic Pharma gets US health regulator FDA's nod for scalp psoriasis treatment drug

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication used to treat moderate-to-severe psoriasis of the scalp.

The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Betamethasone Valerate Foam, the drug firm said in a statement.

The approved ANDA is therapeutically equivalent to the reference listed drug product Luxiq Foam (0.12 per cent), of Norvium Bioscience, LLC (Norvium).

Betamethasone valerate foam is a topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.

Shares of Alembic Pharmaceuticals on Monday ended 0.97 per cent down at Rs 1,089.90 apiece on the BSE.